TRVI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Trevi Therapeutics Inc (TRVI) is not a strong buy at the moment for a beginner investor with a long-term horizon. The company's financial performance shows significant losses, and there are no strong positive catalysts or trading signals to justify an immediate investment. While analysts maintain a Buy/Overweight rating, the recent price target reductions and lack of significant trading trends suggest a cautious approach.
The MACD is negative and contracting, indicating bearish momentum. RSI is neutral at 67.86, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level (R1: 11.895) with a pre-market price of 11.66, showing limited upside potential in the short term.
Analysts maintain Buy/Overweight ratings, and the company has a guided cash runway to fund impactful catalysts in its pipeline for non-IPF ILD, RCC, and Phase 3 IPF studies.
The company reported significant losses in Q4 2025, with net income down -27.15% YoY and EPS dropping -45.45% YoY. There is no recent news or significant trading activity from hedge funds, insiders, or Congress to drive the stock upward.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$8.316 million, down -27.15% YoY. EPS dropped significantly by -45.45% YoY to -0.06, indicating worsening profitability.
Analysts have lowered price targets recently (from $25 to $24 and $19 to $18) but maintain Buy/Overweight ratings. They highlight the company's cash runway and potential catalysts as positives, but the reduced targets reflect tempered expectations.
